Consistent with its role in cancer cell survival [24], potentiated levels of p-Akt and p-S6 were lower in CRs and elevated in clinical NRs, although the two clinical categories were not mutually exclusive since several NR samples had low potentiated PI3K pathway activity (Figure 2C, D). The gene discussed is PIK3CD; the disease is cancer.